Skip to main content

Table 1 Comparison between AS and nrAxSpA

From: Baseline severity of sacroiliitis can predict acute inflammatory status of sacroiliac joint in early axial spondyloarthritis of male patients: a cross sectional study

  nrAxSpA (N = 63) AS (N = 96) P
Age (years) 21.0 [20.0;21.0] 21.0 [20.0;22.0] 0.739
Symptom duration (years) 1.0 [0.3; 2.0] 2.0 [0.5; 3.0] 0.186
Peripheral arthritis (%) 36 (57.1%) 41 (42.7%) 0.105
Enthesitis (%) 25 (39.7%) 16 (16.7%) 0.002
Uveitis (%) 7 (11.1%) 14 (14.6%) 0.694
Dactylitis (%) 3 (4.8%) 1 (1.0%) 0.343
Psoriasis (%) 1 (1.6%) 3 (3.1%) 0.930
Inflammatory bowel disease (%) 0 0 1.000
CRP elevation (%) 23 (37.1%) 61 (63.5%) 0.002
Alternating buttock pain (%) 26 (41.3%) 66 (68.8%) 0.001
Good response to NSAID (%) 42 (66.7%) 61 (63.5%) 0.815
Family history of SpA (%) 9 (14.3%) 13 (13.5%) 1.000
HLA-B27 positivity (%) 49 (77.8%) 85 (88.5%) 0.109
ESR (mm/hr) 2.0 [2.0;11.0] 10.5 [3.0;23.0] < 0.0001
CRP (mg/dL) 0.1 [0.0; 0.8] 0.6 [0.2; 1.6] < 0.0001
Right sacroiliitis grade 1.0 [0.0; 1.0] 3.0 [2.0; 3.0] < 0.0001
Left sacroiliitis grade 1.0 [0.0; 1.5] 3.0 [2.0; 3.0] < 0.0001
mSASSS 0.0 [0.0; 0.0] 0.0 [0.0; 0.0] 0.088
Presence of syndesmophyte (%) 0 (0.0%) 6 (9.2%) 0.110
SPARCC score of BMO (0–48) 4.0 [0.0; 8.5] 12.0 [7.0;19.0] < 0.0001
SPARCC score of intense oedema (0–12) 0.0 [0.0; 0.0] 0.0 [0.0; 0.5] 0.015
SPARCC score of deep oedema (0–12) 0.0 [0.0; 0.0] 2.0 [0.0; 5.5] < 0.0001
Total inflammatory SPARCC score of SIJ (0–72) 5.0 [0.0; 9.5] 14.0 [7.0;25.5] < 0.0001
  1. AS ankylosing spondylitis, BMO bone marrow oedema, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, nrAxSpA non-radiographic axial spondyloarthritis, NSAID nonsteroidal anti-inflammatory drug, SPARCC SPondyloArthritis Research Consortium of Canada